Amoxicillin vs third-generation cephalosporin for infection prophylaxis after third molar extraction
© 2022 Wiley Periodicals LLC..
OBJECTIVES: Although amoxicillin is the first-line prophylactic drug for impacted mandibular third molar extraction, third-generation cephalosporins are widely prescribed in Japan. The lack of real-world evidence may be one reason for this inappropriate use. We evaluated differences in the incidence of surgical site infection between amoxicillin and third-generation cephalosporins for impacted mandibular third molar extraction.
METHODS: Using the JMDC Claims Database, we identified dental visits with fully or horizontally impacted mandibular third molar extraction from April 2015 to March 2020. One-to-one propensity-score matching was conducted between amoxicillin and third-generation cephalosporin groups. The incidence of surgical site infection following extraction was compared in the matched pairs using McNemar's test.
RESULTS: We identified 109,266 dental visits, including 39,514 (36.2%) patients who received amoxicillin and 69,752 (63.8%) patients who received third-generation cephalosporins. In the 39,514 matched pairs, the incidence of surgical site infection was 3.5% (n = 1399) for amoxicillin group and 3.7% (n = 1467) for third-generation cephalosporin group (p = 0.003).
CONCLUSIONS: Amoxicillin was associated with a lower incidence of surgical site infection after impacted mandibular third molar extraction compared with third-generation cephalosporins. This result supports current guidelines and strengthens the importance of disseminating and implementing antimicrobial resistance control in dentistry.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Oral diseases - 30(2024), 2 vom: 17. März, Seite 660-668 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sato, Misuzu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
804826J2HU |
|---|
| Anmerkungen: |
Date Completed 01.03.2024 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/odi.14421 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348358563 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348358563 | ||
| 003 | DE-627 | ||
| 005 | 20240301231917.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/odi.14421 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM348358563 | ||
| 035 | |a (NLM)36321875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sato, Misuzu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Amoxicillin vs third-generation cephalosporin for infection prophylaxis after third molar extraction |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a OBJECTIVES: Although amoxicillin is the first-line prophylactic drug for impacted mandibular third molar extraction, third-generation cephalosporins are widely prescribed in Japan. The lack of real-world evidence may be one reason for this inappropriate use. We evaluated differences in the incidence of surgical site infection between amoxicillin and third-generation cephalosporins for impacted mandibular third molar extraction | ||
| 520 | |a METHODS: Using the JMDC Claims Database, we identified dental visits with fully or horizontally impacted mandibular third molar extraction from April 2015 to March 2020. One-to-one propensity-score matching was conducted between amoxicillin and third-generation cephalosporin groups. The incidence of surgical site infection following extraction was compared in the matched pairs using McNemar's test | ||
| 520 | |a RESULTS: We identified 109,266 dental visits, including 39,514 (36.2%) patients who received amoxicillin and 69,752 (63.8%) patients who received third-generation cephalosporins. In the 39,514 matched pairs, the incidence of surgical site infection was 3.5% (n = 1399) for amoxicillin group and 3.7% (n = 1467) for third-generation cephalosporin group (p = 0.003) | ||
| 520 | |a CONCLUSIONS: Amoxicillin was associated with a lower incidence of surgical site infection after impacted mandibular third molar extraction compared with third-generation cephalosporins. This result supports current guidelines and strengthens the importance of disseminating and implementing antimicrobial resistance control in dentistry | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antimicrobial resistance | |
| 650 | 4 | |a impacted mandibular third molar | |
| 650 | 4 | |a propensity-score matching | |
| 650 | 4 | |a surgical site infection prophylaxis | |
| 650 | 4 | |a tooth extraction | |
| 650 | 7 | |a Amoxicillin |2 NLM | |
| 650 | 7 | |a 804826J2HU |2 NLM | |
| 650 | 7 | |a Cephalosporins |2 NLM | |
| 700 | 1 | |a Yamana, Hayato |e verfasserin |4 aut | |
| 700 | 1 | |a Ono, Sachiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ishimaru, Miho |e verfasserin |4 aut | |
| 700 | 1 | |a Matsui, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Yasunaga, Hideo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral diseases |d 1995 |g 30(2024), 2 vom: 17. März, Seite 660-668 |w (DE-627)NLM075295946 |x 1601-0825 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g day:17 |g month:03 |g pages:660-668 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/odi.14421 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |b 17 |c 03 |h 660-668 | ||